"10.1371_journal.pone.0059252","plos one","2013-03-22T00:00:00Z","Peter Reinhardt; Michael Glatza; Kathrin Hemmer; Yaroslav Tsytsyura; Cora S Thiel; Susanne Höing; Sören Moritz; Juan A Parga; Lydia Wagner; Jan M Bruder; Guangming Wu; Benjamin Schmid; Albrecht Röpke; Jürgen Klingauf; Jens C Schwamborn; Thomas Gasser; Hans R Schöler; Jared Sterneckert","Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, Münster, North Rhine Westphalia, Germany; Stem Cell Biology and Regeneration Group, Institute of Cell Biology, Center for Molecular Biology of Inflammation, Westfälische Wilhelms-Universität Münster, Münster, North Rhine-Westphalia, Germany; Westfälische Wilhelms-Universität Münster, Institute for Medical Physics and Biophysics, Cellular Biophysics Group, Münster, North Rhine-Westphalia, Germany; Center for Research in Molecular Medicine and Chronic Diseases at the University of Santiago de Compostela, Santiago de Compostela, Spain; Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, University of Tübingen, and German Center for Neurodegenerative Diseases, Tübingen, Baden-Württemburg, Germany; Institute for Human Genetics, University of Münster, Münster, North Rhine Westphalia, Germany; Medical Faculty, University of Münster, Münster, North Rhine-Westphalia, Germany","Conceived and designed the experiments: PR SM JS JCS JK TG HRS LW JMB. Performed the experiments: PR MG KH YT CST SH JAP GW BS AR LW JMB. Analyzed the data: PR MG KH YT CST SH JAP GW BS JS SM JCS JK TG HRS AR LW JMB. Contributed reagents/materials/analysis tools: BS TG. Wrote the paper: PR MG JS HRS.","The authors have read the journals policy and have the following conflicts: smNPCs are the subject of the patent application EP 12 00 0143.3 to the European Patent Office on January 11, 2012. Peter Reinhardt, Michael Glatza, Jared Sterneckert, and Hans R. Schöler are inventors on this patent application and may receive royalties from licensees. The claims of this patent specifically cover the derivation of smNPCs from human pluripotent stem cells as well as protocols to direct the differentiation of smNPCs into neural crest lineages, midbrain dopaminergic neurons, and motor neurons. There are no consultancy- or employment-related conflicts of interest. There are no products in development or modified products in development. The patent inventors and the authors of the manuscript declare that this patent application does not alter their adherence to all of the PLOS ONE policies on sharing data and materials as outlined in the guide for authors.","2013","03","Peter Reinhardt","PR",18,TRUE,9,12,18,4,TRUE,TRUE,FALSE,0,NA,FALSE
